Drugs / ARGX-119
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07673601 | Jun → Dec 2026 expected | — | argenx | Recruiting | No outcome recorded |
| Phase 1 | NCT06436742 | Sep 2024 → Aug 2027 expected | congenital myasthenic syndrome | argenx | Recruiting | No outcome recorded |
| Phase 1 | NCT05670704 | Feb 2023 → Aug 2024 | — | argenx | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07287982 | Dec 2025 → May 2029 expected | spinal muscular atrophy | argenx | Recruiting | No outcome recorded |
| Phase 2 | NCT06441682 | Oct 2024 → Aug 2026 overdue | amyotrophic lateral sclerosis | argenx | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-03-06 | argenx | Results argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline argenx.com ↗
Additional results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes (CMS) will also be shared, providing proof-of-concept support based on a favorable safety profile and consistent functional improvements across multiple efficacy measures. |
| 2025-06-30 | argenx | Results argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes argenx.com ↗
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what’s possible. |
| 2025-04-08 | argenx | Results argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP argenx.com ↗
In addition, first-in-human data were presented for the company’s third clinical candidate, ARGX-119 (MuSK agonist), which is being evaluated in disorders of the neuromuscular junction (NMJ), including congenital myasthenic syndromes (CMS). |
All press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARGX-119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06441682 ↗ |
| Known as | 3b2g2m1-hlgg1 laladelk | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068571 ↗ |
| Known as | Adimanebart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07673601 ↗ |
| Action | Activate | “Activation of muscle-specific kinase (MuSK) by ARGX-119 may stabilize and improve NMJ function” NCT07287982 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068571 ↗ |
| Route | Intravenous | “ARGX-119 IV or SC” NCT05670704 ↗ |
| Route | Subcutaneous | “ARGX-119 IV or SC” NCT05670704 ↗ |
| Target | MUSK | “Activation of muscle-specific kinase (MuSK) by ARGX-119 may stabilize and improve NMJ function” NCT07287982 ↗ |